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1. Introduction
Helicobacter pylori (HP) infection is reported to be closely associated with upper gastrointesti‐
nal disorders, such as gastroduodenal ulcers, chronic gastritis, and gastric cancer. Further‐
more, patients with chronic renal failure receiving hemodialysis often complain of digestive
symptoms. There are many possible factors causing these symptoms, including reduced gas‐
trointestinal motility attributable to diabetes mellitus, uremia, intestinal ischemia associated
with circulatory failure, and adverse reactions to many oral medications including non-ster‐
oidal anti-inflammatory drugs. Although HP infection is amongthe factors that may cause
upper gastrointestinal disorders in patients with chronic renal failure, the association
withHP infection has not as yet been elucidated. According to recent reports, the prevalence
of HP infection is significantly lower in patients with chronic renal failure than in controls
with normal renal function, and the prevalence is even reported to decrease with longer du‐
ration of hemodialysis. However, there are also previous reports presenting contrary find‐
ings. This chapter describes HP infection and eradication therapy in hemodialysis patients.
2. Is the prevalence of HP infection low in hemodialysis patients?
It is often reported that the prevalence of HP infection tends to be lower in patients with
chronic renal failure receiving hemodialysis than in control groups with normal renal func‐
tion [1-19]. In a study conducted in 539 hemodialysis patients, the prevalence of HP infec‐
tion was 48.6%, whereas health check-up examinees with normal renal function showed a
significantly higher prevalence of 69.4% (P < 0.001) [15]. Another report also showed that,
compared to a 27.5% prevalence of HP infection in hemodialysis patients, the prevalence in
patients with chronic renal failure not receiving hemodialysis was significantly higher at
56.0% [4]. Although there is a report showing the prevalence of HP infection to also be low
in patients undergoing renal transplantation, it seems that most had received hemodialysis
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before transplantation [3]. Based on the above observations, the prevalence of HP infection
would appear to be low in hemodialysis patients, suggesting that the hemodialysis proce‐
dure itself may be involved in the low prevalence of HP infection.
3. Are duration of hemodialysis and prevalence of HP infection inversely
correlated?
How are duration of hemodialysis and prevalence of HP infection associated? There are re‐
ports that the prevalence of HP infection tends to be lower with longer duration of hemo‐
dialysis [9, 15, 20, 21]. Nakajima et al. report that the prevalence of HP infection gradually
decreases with a 2-year or longer duration of hemodialysis, and Sugimoto et al reported that
the prevalence gradually decreases within 4 years of hemodialysis [15]. Moriyama et al. re‐
port that such a tendency is revealed in patients receiving hemodialysis for 8 years or longer
[20]. There is also a report that the prevalence of HP infection in health check-up examinees
with normal renal function was similar to that in patients with chronic renal failure who had
received hemodialysis for less than 1 year [15]. Meanwhile, other studies have shown that
there is no such association [22, 23]. However, Sugimoto et al. conducted a 4-year follow-up
study in hemodialysis patients with HP infection and found that the prevalence gradually
decreased from 51.6% at the start to 38.3% at the end [15]. Given that the spontaneous elimi‐
nation rate of HP infection is generally reported to be 0.6% annually [24], it must be as‐
sumed from these results that the hemodialysis procedure itself contributes to the observed
decrease in the prevalence of HP infection.
4. Is there variation in HP infection rates among different countries?
The gastricmucosa of approximately 50% of the world’s populationis infected with HP, and
the infectionlevels exceed 70% in some developing areas [25, 26].
There is variation in HP infection ratesamong different countries. It may, therefore, be impor‐
tant to evaluate the infection rate in various countries. In East Asian countries, the prevalence
of HPinfection in patients receiving chronic hemodialysis is44.5% (95% confidence interval
(CI): 41.5–47.6%], 474/1065), which is significantly lower than in all patients with nor malrenal
function [54.0% [95% CI: 50.9–57.1%], 560/1038,P <0.001] [27]. On the other hand, because the
prevalenceof HPin other areas, such as Europe, Middle East, and South Asia has a wide varia‐
tion, it isdifficult to evaluate the prevalence of HPinfectionin those areas.
5. Why does the hemodialysis procedure reduce the prevalence of HP
infection?
One reason is eradication of HPby antibiotics that are administeredas therapy for other in‐
fections experienced by hemodialysis patients. Antibiotics are the most typically prescribed
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drugs in general. In hemodialysis patients, antibiotics may be used for the treatment of bac‐
terial infections as often as or even more frequently than in the general population. It is as‐
sumed that patients with renal failure are often prescribed reduced doses of antibiotics.
However, compared to the general population with normal renal function, blood levels of
antibiotics are likely to be higher after administration in patients with renal failure, and the
elimination time is expected to be longer. Thus, in hemodialysis patients with a long dura‐
tion of renal failure, the spontaneous elimination rate of HP infection might be increased by
repeated administration of antibiotics. Because blood urea levels are increased in hemodial‐
ysis patients, urea levels in gastric juice are also high. The increased urea levels are consid‐
ered to suppress the growth of HP in the stomach [28]. Another possible explanation is that
up-regulation of pro-inflammatory cytokines in hemodialysis patients triggers the infiltra‐
tion of inflammatory cells activated by the gastric mucosa, resulting in progression of gastric
mucosal atrophy, an increase in pH, and ultimately HP elimination [29, 30]. While there are
as yet no data clearly supporting this explanation, the prevalence of HP infection may be de‐
creased by a combination of various factors.
6. What are the harmful effects of a decreased prevalence of HP infection
on hemodialysis patients?
In general, HP infection is considered to be a cause of gastroduodenal ulcers, and a decrease
in the prevalence of HP infection is favorable in this regard. It is widely known that HP
eradication suppresses gastric acid secretion, which causes gastric erosion [31]. The frequen‐
cy of endoscopically detected gastric erosion is reported to be high in hemodialysis patients
[20, 32, 33], which may be associated with a decrease in HP infection. Because gastric erosion
may cause gastrointestinal bleeding, caution is required especially in hemodialysis patients
[20]. They are often receiving anticoagulant or antiplatelet drugs, and gastrointestinal bleed‐
ing can thus be fatal.
Prophylactic administration of anti-acid secretory drugs, such as proton pump inhibitors
(PPI), is recommended. While long-term hemodialysis is reported to carry a high risk for re‐
flux esophagitis [32-34], this may also be attributable to suppressedgastric acid secretion due
to a decrease in HP infection. In patients receiving long-term hemodialysis, administration
of anti-acid secretory drugs is recommended to prevent reflux esophagitis.
7. Is HP eradication necessary for hemodialysis patients?
While the previous section described the harmful effects of a reduced prevalence of HP in‐
fection on hemodialysis patients, the harmful effects of HP infection include the aforemen‐
tioned association with gastroduodenal ulcers, chronic gastritis and gastric cancer, as well as
gastric mucosa associated-lymphoid tissue lymphoma, etc. Especially in hemodialysis pa‐
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tients, the frequency of gastroduodenal ulcers and gastric cancer is reported to be higher
than in healthy people [3, 35]. Because hemodialysis patients are often receiving anticoagu‐
lant or antiplatelet drugs, bleeding from gastroduodenal ulcers may be fatal. Thus, HP erad‐
ication is considered to be an important treatment for hemodialysis patients in order to
prevent gastroduodenal ulcers and gastric cancer. Although spontaneous elimination of HP
infection can be expected in hemodialysis patients, the earliest possible HP eradication is
recommended especially in those with a history of gastroduodenal ulcer and confirmed cur‐
rent HP infection.
8. How is HP eradication best achieved in hemodialysis patients?
According to recent reports, the major regimen is a combination of a PPI selected from
among omeprazole, lansoprazole, and esomeprazole and 2 antibiotics selected from among
clarithromycin, amoxicillin, and metronidazole, which are administered for 1 or 2 weeks [1,
6, 36-40]. Although the eradication rate fluctuates slightly from 72.7 to 96.0%, it averages
around 90%. There seems to be no substantial difference in comparison with the eradication
rate of HP infection in the general population. The factors contributing to eradication failure
include a history of previous eradication therapy, suggesting that the presence or absence of
resistant strains to antibiotics iskey to the success of eradication therapy [6].
9. What are the precautions for HP eradication therapy in hemodialysis
patients?
Caution should be considered in performing eradication therapy for hemodialysis patients
to avoidexcessive doses of drugs. Administration of low doses results in high blood levels.
However, hemodialysis removes both PPI and antibiotics, lowering their blood levels. In
consideration of this fact, without adjustment of the therapy by administering the drugs af‐
ter the hemodialysis session on the day of hemodialysis, the eradication rate of HP infection
may be decreased. Safe and effective optimal dosages and administration procedures should
be established. In patients with chronic renal failure before the initiation of hemodialysis, at‐
tention should be paid to the nephrotoxicity of amoxicillin, and the eradication therapy
needs to be adjusted by substituting amoxicillin with metronidazole [39, 41, 42].
Moreover, hemodialysis patients often receive oral antibiotics, and the duration of circula‐
tion of these antibiotics in the body is prolonged due to delayed metabolism. Thus, it seems
that HP often acquires resistance to antibiotics. According to a report on resistance to clari‐
thromycin, resistant HP strains were detected in 36.4% of patients with renal failure and
15.2% of healthy volunteers, showing the prevalence of resistant HP strains to be significant‐
ly lower in the latter [43].
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10. Conclusion
This chapter has described HP infection in hemodialysis patients. Because the prevalence of
HP infection is lower in these patients than in healthy people, attention should be paid to
symptoms due to gastric hyperacidity. For those with HP infection, eradication therapy is
recommended in order to prevent gastrointestinal ulcers and gastric cancer. Even after HP
eradication, prophylaxis against gastric erosion and reflux esophagitis should be performed
with anti-acid secretory drugs.
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